ObvioHealth, a NYC-based global Virtual Research Organization (VRO), raised $31m in funding.
The round was led by new investors Dedalus Group, an international healthcare IT and diagnostic software provider, and Novotech Health Holdings Pte. Ltd., Asia Pacific’s biotech-specialist CRO.
The company intends to use the funds to:
- boost the IT capabilities of its proprietary ecosystem and platform for conducting virtual clinical trials, including the GDPR compliant bridging software to query EHR data, and
- make key hires in the coming year, particularly in Asia, with plans to expand the Singapore office into a technology hub.
Led by Ivan Jarry, CEO, ObvioHealth is an end-to-end Virtual Research Organization (VRO) that delivers data to sponsors and a clinical trial experience for participants. The company developed and launched one of the first DCT apps, downloadable on smartphones enabling people to participate in clinical trials from home. In the 4 years since launch, the company has been awarded nearly 40 studies from 28 blue chip clients, implemented in 28 countries, in 16 different therapeutic areas.